Literature DB >> 22688732

A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma.

Juanita J Evans1, Henry S Crist, Saima Durvesh, Richard D Bruggeman, David Goldenberg.   

Abstract

Anaplastic thyroid carcinoma (ATC) is an extremely aggressive and rapidly fatal neoplasm. The aim of this study was to identify a limited cell cycle associated protein expression pattern unique to ATC and to correlate that pattern with clinical outcome. This represents one of the largest tissue micro-array projects comparing the cell cycle protein expression data of ATC to other well-differentiated tumors in the literature. Tissue microarrays were created from 21 patients with ATC and an age and gender matched cohort of patients with papillary thyroid carcinoma (PTC). Expression of epidermal growth factor receptor, cyclin D1, cyclin E, p53, p21, p16, aurora kinase A, opioid growth factor (OGF), OGF-receptor, thyroglobulin and Ki-67 was evaluated in a semi-quantitative fashion. Differences in protein expression between the cohorts were evaluated using chi-square tests with Bonferroni adjustments. Survival time and presence of metastasis at presentation were collected. The ATC cohort showed a statistically significant decrease (p < 0.05) in thyroglobulin expression and statistically significant increases (p < 0.05) in Ki-67 and p53 expression as compared with the PTC cohort. A trend toward loss of p16 and p21 expression was noted in the ATC cohort. A trend toward decreased survival was noted with p21 expression. These data indicate disruption of the normal cell cycle with aberrant expression of multiple protein markers suggesting increased proliferative activity and loss of control of cell cycle progression to G₁ phase. These findings support the assertion that ATC may represent the furthest end of a continuum of thyroid carcinoma dedifferentiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22688732     DOI: 10.4161/cbt.20560

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

1.  The differences of regulatory networks between papillary and anaplastic thyroid carcinoma: an integrative transcriptomics study.

Authors:  Zongfu Pan; Lu Li; Yangyang Qian; Xinyang Ge; Xiaoping Hu; Yiwen Zhang; Minghua Ge; Ping Huang
Journal:  Cancer Biol Ther       Date:  2020-08-23       Impact factor: 4.742

Review 2.  Opioids and Cancer Mortality.

Authors:  Jaya Amaram-Davila; Mellar Davis; Akhila Reddy
Journal:  Curr Treat Options Oncol       Date:  2020-02-20

3.  Simvastatin Inhibits Cell Proliferation and Migration in Human Anaplastic Thyroid Cancer.

Authors:  Mei-Chieh Chen; Yuan-Chin Tsai; Jen-Ho Tseng; Jr-Jiun Liou; Steve Horng; Heng-Ching Wen; Yu-Ching Fan; Wen-Bin Zhong; Sung-Po Hsu
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

4.  REGγ Is Associated with Lymph Node Metastasis and T-Stage in Papillary Thyroid Carcinoma.

Authors:  Long Qi; Wei He
Journal:  Med Sci Monit       Date:  2018-03-06

5.  Novel Prognostic Factors Associated with Cell Cycle Control in Sporadic Medullary Thyroid Cancer Patients.

Authors:  Raffaele Pezzani; Loris Bertazza; Elisabetta Cavedon; Simona Censi; Jacopo Manso; Sara Watutantrige-Fernando; Gianmaria Pennelli; Francesca Galuppini; Susi Barollo; Caterina Mian
Journal:  Int J Endocrinol       Date:  2019-02-18       Impact factor: 3.257

6.  A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.

Authors:  Wen-Bin Zhong; Yuan-Chin Tsai; Li-Han Chin; Jen-Ho Tseng; Li-Wen Tang; Steve Horng; Yu-Ching Fan; Sung-Po Hsu
Journal:  Int J Mol Sci       Date:  2018-06-22       Impact factor: 5.923

7.  Meta-analysis of microarray datasets identify several chromosome segregation-related cancer/testis genes potentially contributing to anaplastic thyroid carcinoma.

Authors:  Mu Liu; Yu-Lu Qiu; Tong Jin; Yin Zhou; Zhi-Yuan Mao; Yong-Jie Zhang
Journal:  PeerJ       Date:  2018-10-24       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.